RXi, Danish hospital to research cancer treatment
Brad Kane
Geert Cauwenbergh, president and CEO, RXi Pharmaceuticals Corp., Marlborough.
Marlborough drugmaker RXI Pharmaceuticals Corp. on Friday announced a collaborative research agreement with the Center for Cancer Immune Therapy at Herlev Hospital in Denmark to evaluate the company’s cancer treatment drugs.
The research will center around RXi’s self-delivering RNAi technology platform in tumor infiltrating lymphocytes for use in treating various types of cancers, including melanoma and ovarian cancer.
It’s one of at least three such research agreements the company has announced this year. The two others were French cancer institute Gustave Roussy, and Norwegian research firm PCI Biotech.
In a statement, Vice President of Research Karen Bullock said the collaboration, along with others, will be key cornerstones in the company’s efforts to begin clinical trials, which the company hopes to achieve within the next 12 to 18 months.
WBJ Web Partners
Most Recent
Most Recent
0 Comments